Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Liquid Biopsy and Precision Oncology
share announcement

Liquid Biopsy and Precision Oncology

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (15 October 2022) | Viewed by 4524

Special Issue Editors

Dr. Chiara Nicolazzo

E-Mail Website
Guest Editor
Cancer Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
Interests: circulating tumor cells; circulating tumor DNA; liquid biopsy; liquid biopsy devices; in vitro models; tumor biology; drug resistance; molecular oncology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Paola Gazzaniga

E-Mail
Guest Editor
Chief Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy
Interests: liquid biospy-driven clinical trials; cancer heterogeneity; clonal evolution; precision oncology; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

Liquid biopsy, the analysis of tumors using biomarkers circulating in body fluids, has emerged as a promising non-invasive tool for cancer management. Much attention was paid to circulating tumor cells (CTCs) first, followed by circulating tumor DNA (ctDNA), extracellular vesicles and other tumor-derived products. The growing demand for predictive biomarkers for targeted therapy and the availability of advanced and highly sensitive technologies have brought ctDNA analysis into clinical practice. However, the liquid biopsy is not restricted to molecular profiling but also allows information on tumor biology to be gained through the real-time assessment of the evolving landscape of cancer. Therefore, it is only right to integrate all the information about the different products released into fluids by tumors in order to monitor cancer progression.

This Special Issue of Diagnostics will cover all the different aspects of liquid biopsy, from the pre-analytical phase to clinical impact, in order to assemble a huge corpus of cancer precision medicine knowledge. Particularly, but not exclusively, welcome are papers aimed at matching and integrating information derived from different liquid biopsy sources.

Dr. Chiara Nicolazzo
Prof. Dr. Paola Gazzaniga
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • circulating tumor cells (CTCs)
  • circulating tumor DNA (ctDNA)
  • extracellular vesicles (EVs)
  • tumor-educated platelets (TEPs)
  • protein biomarkers
  • epigenetic biomarkers in CTCs and ctDNA
  • pre-analytical, analytical and post-analytical phases
  • technologies
  • tumor heterogeneity
  • cancer diagnosis
  • early detection
  • prognosis
  • therapeutic targets and resistance
  • minimal residual disease
  • risk of relapse

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

7 pages, 204 KiB  
Communication
Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments
by Chiara Nicolazzo, Alain Gelibter, Irene Bottillo, Francesca Belardinilli, Simona Pisegna, Gianluigi De Renzi, Daniele Marinelli, Paola Grammatico, Enrico Cortesi, Giuseppe Giannini and Paola Gazzaniga
Diagnostics 2021, 11(12), 2196; https://doi.org/10.3390/diagnostics11122196 - 25 Nov 2021
Cited by 4 | Viewed by 1547
Abstract
Although molecular profiling at diagnosis has traditionally relied on direct sampling of neoplastic tissue, cancer clonal evolution represents a critical obstacle to use primary tissue biopsies to guide clinical decision-making at the time of progressive disease. Liquid biopsies might offer enormous advantages over [...] Read more.
Although molecular profiling at diagnosis has traditionally relied on direct sampling of neoplastic tissue, cancer clonal evolution represents a critical obstacle to use primary tissue biopsies to guide clinical decision-making at the time of progressive disease. Liquid biopsies might offer enormous advantages over tissue biopsies, tracking in real-time temporal-based tumor dynamics following each line of treatment. Here, we compared two liquid biopsy assays, specifically real-time polymerase chain reaction and next-generation sequencing, to track the KRAS G12C mutation at onset of progression from previous lines of therapy. The KRAS G12C mutation was acquired at the time of progressive disease in 24% of patients. Furthermore, all patients with KRAS G12C mutation-positive tissue became negative in ctDNA at progressive disease. The presence of other somatic mutations in all these samples confirmed the tumor origin of the circulating DNA. This pilot study suggests that in the assessment of the plasma KRAS G12C mutation as a druggable target, real-time PCR assay Idylla might be a suitable approach to better match patients to interventional biomarker-targeted therapies. Full article
(This article belongs to the Special Issue Liquid Biopsy and Precision Oncology)

Review

Jump to: Research

16 pages, 10107 KiB  
Review
Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
by Brahim El Hejjioui, Laila Bouguenouch, Moulay Abdelilah Melhouf, Hind El Mouhi and Sanae Bennis
Diagnostics 2023, 13(3), 470; https://doi.org/10.3390/diagnostics13030470 - 27 Jan 2023
Cited by 1 | Viewed by 2018
Abstract
Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes according to the molecular landscape of the tumor. Triple-negative breast cancer is a subtype associated with higher tumor aggressiveness, poor prognosis, and poor response to treatment. In metastatic breast cancer, [...] Read more.
Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes according to the molecular landscape of the tumor. Triple-negative breast cancer is a subtype associated with higher tumor aggressiveness, poor prognosis, and poor response to treatment. In metastatic breast cancer, approximately 6% to 10% of new breast cancer cases are initially staged IV (de novo metastatic disease). The number of metastatic recurrences is estimated to be 20–30% of all existing breast tumor cases, whereby the need to develop specific genetic markers to improve the prognosis of patients suffering from these deadly forms of breast cancer. As an alternative, liquid biopsy methods can minutely identify the molecular architecture of breast cancer, including aggressive forms, which provides new perspectives for more precise diagnosis and more effective therapeutics. This review aimed to summarize the current clinical evidence for the application of circulating tumor DNA in managing breast cancer by detailing the increased usefulness of this biomarker as a diagnostic, prognostic, monitoring, and surveillance marker for breast cancer. Full article
(This article belongs to the Special Issue Liquid Biopsy and Precision Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop